UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted alpha-particle immunotherapy for acute myeloid leukemia

American Society of Clinical Oncology educational book, 2014 (34), p.e126-e131

2014

Volltextzugriff (PDF)

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1317-1326

2017

Volltextzugriff (PDF)

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of clinical oncology, 2022-09, Vol.40 (26), p.3032-3036

2022

Volltextzugriff (PDF)

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

Clinical cancer research, 2022-05, Vol.28 (10), p.2030-2037

2022

Volltextzugriff (PDF)

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

Clinical cancer research, 2010-11, Vol.16 (21), p.5303-5311

2010

Volltextzugriff (PDF)

Sweet Syndrome in the Central Nervous System: A Case of Orbital Inflammation, Sixth Nerve Palsy, and Pachymeningitis

Journal of neuro-ophthalmology, 2024-09

2024

Volltextzugriff (PDF)

Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions

Hematology/oncology clinics of North America, 2011-12, Vol.25 (6), p.1189-1213

2011

Volltextzugriff (PDF)

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death

Leukemia research, 2013-09, Vol.37 (9), p.1004-1009

2013

Volltextzugriff (PDF)

Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia

Acta haematologica, 2013-01, Vol.129 (1), p.48-54

2013

Volltextzugriff (PDF)

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Blood, 2022-11, Vol.140 (Supplement 1), p.9893-9895

2022

Volltextzugriff (PDF)

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Blood, 2023-11, Vol.142 (Supplement 1), p.3274-3274

2023

Volltextzugriff (PDF)

High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Blood, 2021-11, Vol.138 (Supplement 1), p.1555-1555

2021

Volltextzugriff (PDF)

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Blood, 2019-11, Vol.134 (Supplement_1), p.3899-3899

2019

Volltextzugriff (PDF)

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.12-14

2020

Volltextzugriff (PDF)

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab

Clinical cancer research, 2022-05, Vol.28 (10), p.2030-2037

2022

Volltextzugriff (PDF)

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Blood, 2021-11, Vol.138 (Supplement 1), p.2318-2318

2021

Volltextzugriff (PDF)

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

Blood, 2019-11, Vol.134 (Supplement_1), p.2957-2957

2019

Volltextzugriff (PDF)

AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S246-S247

2022

Volltextzugriff (PDF)

Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S126

2022

Volltextzugriff (PDF)

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Blood, 2016-12, Vol.128 (22), p.2816-2816

2016

Volltextzugriff (PDF)

Phase 2 study of guadecitabine (SGI-110), a novel hypomethylating agent, in treatment-naïve patients with acute myeloid leukaemia who are not candidates for intensive chemotherapy

The lancet oncology, 2017-08, Vol.18 (10), p.1317-1326

2017

Volltextzugriff (PDF)

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7005-7005

2016

Volltextzugriff (PDF)

Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions: Acute Leukemia

Hematology/oncology clinics of North America, 2011, Vol.25 (6)

2011

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(47)
Buchkapitel
(3)

Sprache

Englisch
(50)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Adult
(7)
Middle Aged
(6)
Oncology
(6)
Aged
(4)
Female
(4)
Male
(4)
Aged, 80 And Over
(3)
Hematology
(3)
Immunoconjugates - Therapeutic Use
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)
Remission Induction
(3)
Young Adult
(3)
Acute Myeloid Leukemia
(2)
Adolescent
(2)
Alpha Particles - Adverse Effects
(2)
Alpha Particles - Therapeutic Use
(2)
Antibodies, Monoclonal, Humanized
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeted alpha-particle immunotherapy for acute myeloid leukemia

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

Sweet Syndrome in the Central Nervous System: A Case of Orbital Inflammation, Sixth Nerve Palsy, and Pachymeningitis

Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death

Translocation t(11;17) in de novo Myelodysplastic Syndrome Not Associated with Acute Myeloid or Acute Promyelocytic Leukemia

Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nano-Generator Actinium-225-Lintuzumab

Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration

AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Phase 2 study of guadecitabine (SGI-110), a novel hypomethylating agent, in treatment-naïve patients with acute myeloid leukaemia who are not candidates for intensive chemotherapy

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)

Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions: Acute Leukemia

Suchergebnisse filtern